Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avanos Medical (AVNS) EPS (Weighted Average and Diluted) (2016 - 2025)

Avanos Medical's EPS (Weighted Average and Diluted) history spans 11 years, with the latest figure at $0.12 for Q3 2024.

  • For Q3 2024, EPS (Weighted Average and Diluted) rose 163.16% year-over-year to $0.12; the TTM value through Sep 2024 reached $0.43, up 279.17%, while the annual FY2023 figure was -$0.21, 145.65% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2024 was $0.12 at Avanos Medical, up from $0.09 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.78 in Q2 2021 and bottomed at -$1.03 in Q4 2020.
  • The 5-year median for EPS (Weighted Average and Diluted) is $0.08 (2020), against an average of -$0.0.
  • The largest annual shift saw EPS (Weighted Average and Diluted) plummeted 758.33% in 2020 before it surged 1400.0% in 2021.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.03 in 2020, then surged by 123.3% to $0.24 in 2021, then dropped by 12.5% to $0.21 in 2022, then grew by 14.29% to $0.24 in 2023, then plummeted by 50.0% to $0.12 in 2024.
  • Per Business Quant, the three most recent readings for AVNS's EPS (Weighted Average and Diluted) are $0.12 (Q3 2024), $0.09 (Q2 2024), and -$0.02 (Q1 2024).